MNMD
vs
S&P 500
MNMD
S&P 500
Over the past 12 months, MNMD has significantly outperformed S&P 500, delivering a return of +147% compared to the S&P 500's +15% growth.
Stocks Performance
MNMD vs S&P 500
Performance Gap
MNMD vs S&P 500
Performance By Year
MNMD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Mind Medicine (MindMed) Inc
Glance View
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.
